Patent Trial and Appeal Board (PTAB) is not favorable to patent owners, to keep it lightly, according to a report issued by Biologics HQ in the interval of PTB box owners Pharma for Pharma, a search database of drugs, patents, And the companies involved in the review of PTAB Interstate (IPR) Proceedings developed by lawyers in Fizpatrick Kaila, Harper and Scinto. There is a very different story in the Biologics HQ report in the case of drug patents facing PTR’s IPR challenges. The Orange Book, Center for Drug Evaluation and Research (CDER) on US Inventions Act (AIA) tests published by PATAB shows on the combination of data sources, including biology and statistics listed. The biologics HQ report concludes that, despite the widespread concern about the problem of the patent death of the PTAB operative in the IPR, “such concern is not appropriate for the drug patent.”

As per March 21, 2017 IPR data released by PTAB, 53 percent IPRs were resolved by March 31, 2017; Some other proposals have been denied before the organization’s decision or the institution’s decision is denied. As a result of 35 percent of all resolved IPRs, the final decision was made and 23 percent gave birth to the findings of unrestraining of all claims. No instituted claim was found unpatentable in 50 percent of final written decisions.

Biological drug patent is better than Pharmaceutical drug
The CDER-listed biologic drug patent also survives from PTAB, does not have better challenges compared to patents compared to patents, although the number of comparative challenges is comparatively very low, by 31 March 2017, biologics HQ It is reported that in total 29 Hull IPR petitions include patents covering CDER-listed biology. 41% of those petitions were established and 28 percent reached the final decision. 17 percent of all solved CDER-listed biological drugs unrestricted the final written decisions of all claims, and 10 percent led the last written decision without claim claims.

CDER-listed biologics
In terms of settlements, biologics HQ data shows that 21 percent of all IPRs included in CDER-listed biology were fixed before the institution. It is for all the settlements in the IPR associated with CDER-listed biology. 17 percent of Orange Book IPRs, 12 percent before institution and 5 percent later. For all the technologies, 30 percent of all resolved IPR agreements reached, but only 17 percent of the settlements were settled before the institution.

Comparing written decision
While comparing the final written decisions between all the IPRs, the IPR related to the Orange Book Patent, and the CDR-listed biological drug patent-related IPR, Orange Book and CDER-listed biological drug patents are more likely to be avoided with all claims. For all resolved IPRs, 23 percent did not lead underlying written decisions of all claims. This Orange Book is more than 16 percent of the IPR, and CDER-listed biologic medicine has been led by 17 percent of the IPR for the last written decision, where all claims are unrestricted, 7 percent of all IPRs without final claims of claims Inspired, the CDER-listed biological drug is less than 10 percent of the IPR and less than 19 percent of the orange book IPR, which was met by the same fate.

Determination made by the PTAB ,BiologicsHQ looks!
BiologicsHQ report appears on the outcome of the determination made by PTAB alone, resulting in the end of settlements or other closing results in the form of a decision between the two parties, considering all the technologies, 41% of the IPR ended as a result of PTAB fixation As a result of at least some claims remaining patentable. This includes the final verdict of the claims without the claims of the organization, which are without accountable or mixed claims. Overall, 58 percent IPRs included in drug patents resolved by PTAB have resulted in some patentable claims: 60 percent orange book IPR and 45 percent for CDER-listed biological IPR.

Drugs patents fare better at the PTAB
According to the partner Robert Schwartz in Fitzpatrick, he indicated that the claims of patents covering pharmaceuticals can be prepared more carefully or more opportunity for non-identification through proof of better unpredictable results for patent owners May be. According to Schwartz, “There is so much to do with this fact that in general medicine technologies are more complex than other technologies. He also said that A low rate of lower institution for Orange Book and CDER-listed biologic patent IPR can be a contributing factor, because why more than those patents live with at least some claims “do not try to establish the name of the game Used to be
Once you become established, the possibility of continuing the claim becomes worse. “It was not to say that the decision to set up the institute essentially invalidates the claims, he said. In many cases, they will establish a test if evidence of both sides makes it difficult to be a clear winner. Will give an opportunity to exclude the debate.

PTAB often shows a misleading picture as the number of challenging claims, which eventually become illegal, it is possible that a large percentage of the Orange Book and CDER-listed biology patent claims have become invalid in comparison to the biologics HQ report, because each Petition is counted separately if there are many challenges for the same patent with different results. One of the writers of Fitzpatrick’s biologist and biologist HQ report, April Brian said that the biological HQ team has told the basis of their data on PTAB data that they want to compare apples to an apple. Breyer noted that there is a lot of work involved in compiling this data, including the identification of petitions related to reading each petition and identification of biological related petitions. “No one has taken USPTO statistics for all the technologies and different petitions such as we are specifically for drug patents.
In addition to the recent report, biologic HQ also provides a searchable online database about CDER-listed biologic drug patent challenges in PATAB. As the trends appear, a statistical page of biologics HQ shows the reports of trends and reports, which provide matrix which can be useful for making strategic decisions.